Trials / Terminated
TerminatedNCT05636267
Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients
A Multicenter, Open-Label, Phase Ib/II Study of AK119 and AK112 With or Without Chemotherapy in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Failed to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 59 (actual)
- Sponsor
- Akeso · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase Ib/II study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of AK119 and AK112 With or Without Chemotherapy for NSCLC patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AK119 | AK119 IV every 3 weeks. |
| DRUG | AK112 | AK112 IV every 3 weeks. |
| DRUG | Pemetrexed | Pemetrexed IV every 3 weeks. |
| DRUG | Carboplatin | Carboplatin IV every 3 weeks. |
Timeline
- Start date
- 2023-02-10
- Primary completion
- 2025-02-24
- Completion
- 2025-04-15
- First posted
- 2022-12-05
- Last updated
- 2026-03-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05636267. Inclusion in this directory is not an endorsement.